Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 27


Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial.

Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, Taylor V, Garland C, Frank G, Lane D, Mason E, McNeeley SG, Ascensao J, Chlebowski RT; Women's Health Initiative Investigators.

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2609-18. doi: 10.1158/1055-9965.EPI-08-0385. Epub 2008 Sep 30.


Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators.

JAMA. 2008 Mar 5;299(9):1036-45. doi: 10.1001/jama.299.9.1036.


Hormone replacement therapy, body mass, and the risk of colorectal cancer among postmenopausal women from Germany.

Hoffmeister M, Raum E, Winter J, Chang-Claude J, Brenner H.

Br J Cancer. 2007 Dec 3;97(11):1486-92. Epub 2007 Nov 6.


Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women.

Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, Thibodeau SN, Potter JD.

Cancer Res. 2007 Aug 1;67(15):7534-9.


Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer.

Campbell PT, Newcomb P, Gallinger S, Cotterchio M, McLaughlin JR.

Cancer Causes Control. 2007 Sep;18(7):723-33. Epub 2007 Jun 5.


Hormone replacement therapy and survival after colorectal cancer diagnosis.

Chan JA, Meyerhardt JA, Chan AT, Giovannucci EL, Colditz GA, Fuchs CS.

J Clin Oncol. 2006 Dec 20;24(36):5680-6.


Body mass index and the risk of death following the diagnosis of colorectal cancer in postmenopausal women (United States).

Doria-Rose VP, Newcomb PA, Morimoto LM, Hampton JM, Trentham-Dietz A.

Cancer Causes Control. 2006 Feb;17(1):63-70.


Hormone replacement therapy for breast cancer survivors: an answered question?

Zielinski SL.

J Natl Cancer Inst. 2005 Jul 6;97(13):955. No abstract available.


Oral contraceptive use, reproductive factors, and colorectal cancer risk: findings from Wisconsin.

Nichols HB, Trentham-Dietz A, Hampton JM, Newcomb PA.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1212-8.


Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee.

JAMA. 2004 Apr 14;291(14):1701-12.


Estrogen plus progestin and colorectal cancer in postmenopausal women.

Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E; Women's Health Initiative Investigators.

N Engl J Med. 2004 Mar 4;350(10):991-1004.


Hormone replacement therapy in relation to survival in women diagnosed with colon cancer.

Mandelson MT, Miglioretti D, Newcomb PA, Harrison R, Potter JD.

Cancer Causes Control. 2003 Dec;14(10):979-84.


The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women.

Csizmadi I, Collet JP, Benedetti A, Boivin JF, Hanley JA.

Br J Cancer. 2004 Jan 12;90(1):76-81.


National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Hersh AL, Stefanick ML, Stafford RS.

JAMA. 2004 Jan 7;291(1):47-53.


Hormone replacement therapy and endometrial, ovarian and colorectal cancer.

Gambacciani M, Monteleone P, Sacco A, Genazzani AR.

Best Pract Res Clin Endocrinol Metab. 2003 Mar;17(1):139-47. Review.


Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators.

JAMA. 2002 Jul 17;288(3):321-33.


Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer.

Campbell-Thompson M, Lynch IJ, Bhardwaj B.

Cancer Res. 2001 Jan 15;61(2):632-40.


A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer.

Prihartono N, Palmer JR, Louik C, Shapiro S, Rosenberg L.

Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):443-7.


Hormone replacement therapy and improved survival among postmenopausal women diagnosed with colon cancer (USA).

Slattery ML, Anderson K, Samowitz W, Edwards SL, Curtin K, Caan B, Potter JD.

Cancer Causes Control. 1999 Oct;10(5):467-73.


Colorectal cancer: molecules and populations.

Potter JD.

J Natl Cancer Inst. 1999 Jun 2;91(11):916-32. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk